C-Rad
Market Cap
kr1.2b
Last Updated
2020/10/26 22:20 UTC
Data Sources
Company Financials
Executive Summary
C-Rad AB (publ), together with its subsidiaries, develops, manufactures, and sells systems with applications in radiation therapy for the treatment of cancer worldwide. More Details
Risk Analysis
Snowflake Analysis
Flawless balance sheet with weak fundamentals.
Similar Companies
Share Price & News
How has C-Rad's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CRAD B has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
-4.7%
CRAD B
-7.1%
SE Medical Equipment
-4.2%
SE Market
1 Year Return
16.3%
CRAD B
11.7%
SE Medical Equipment
9.5%
SE Market
Return vs Industry: CRAD B matched the Swedish Medical Equipment industry which returned 15.7% over the past year.
Return vs Market: CRAD B exceeded the Swedish Market which returned 13.4% over the past year.
Shareholder returns
| CRAD B | Industry | Market | |
|---|---|---|---|
| 7 Day | -4.7% | -7.1% | -4.2% |
| 30 Day | 2.8% | -4.7% | -0.8% |
| 90 Day | 14.3% | -0.3% | 3.6% |
| 1 Year | 16.3%16.3% | 13.3%11.7% | 11.5%9.5% |
| 3 Year | 1.4%1.4% | 59.0%40.7% | 27.5%13.8% |
| 5 Year | 108.8%106.2% | 62.3%34.5% | 54.0%24.2% |
Price Volatility Vs. Market
How volatile is C-Rad's share price compared to the market and industry in the last 5 years?
Simply Wall St News
6 days ago | Simply Wall St
What We Learned About C-Rad's (STO:CRAD B) CEO Compensation3 weeks ago | Simply Wall St
Is C-Rad AB (publ) (STO:CRAD B) Popular Amongst Insiders?1 month ago | Simply Wall St
If You Had Bought C-Rad (STO:CRAD B) Shares Five Years Ago You'd Have Earned123% ReturnsValuation
Is C-Rad undervalued compared to its fair value and its price relative to the market?
6.49x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: CRAD B (SEK36.7) is trading above our estimate of fair value (SEK12.94)
Significantly Below Fair Value: CRAD B is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: CRAD B is unprofitable, so we can't compare its PE Ratio to the SE Medical Equipment industry average.
PE vs Market: CRAD B is unprofitable, so we can't compare its PE Ratio to the Swedish market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CRAD B's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CRAD B is overvalued based on its PB Ratio (6.5x) compared to the SE Medical Equipment industry average (4.5x).
Next Steps
Future Growth
How is C-Rad forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
22.0%
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as C-Rad has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Next Steps
- Examine C-Rad's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- C-Rad competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Healthcare industry.
Past Performance
How has C-Rad performed over the past 5 years?
36.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CRAD B is currently unprofitable.
Growing Profit Margin: CRAD B is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CRAD B is unprofitable, but has reduced losses over the past 5 years at a rate of 36.6% per year.
Accelerating Growth: Unable to compare CRAD B's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CRAD B is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (18.4%).
Return on Equity
High ROE: CRAD B has a negative Return on Equity (-5.57%), as it is currently unprofitable.
Next Steps
Financial Health
How is C-Rad's financial position?
Financial Position Analysis
Short Term Liabilities: CRAD B's short term assets (SEK201.8M) exceed its short term liabilities (SEK55.3M).
Long Term Liabilities: CRAD B's short term assets (SEK201.8M) exceed its long term liabilities (SEK7.3M).
Debt to Equity History and Analysis
Debt Level: CRAD B is debt free.
Reducing Debt: CRAD B has no debt compared to 5 years ago when its debt to equity ratio was 28.5%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable CRAD B has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: CRAD B is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 24.5% per year.
Next Steps
Dividend
What is C-Rad current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CRAD B's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CRAD B's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CRAD B's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CRAD B's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CRAD B's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.2yrs
Average management tenure
CEO
Tim Thurn (39 yo)
7.25yrs
Tenure
kr2,117,000
Compensation
Mr. Tim Thurn has been the Chief Executive Officer and President of C-Rad AB since July 1, 2013. Mr. Thurn has been the Chief Executive Officer of C-Rad Imaging AB since 2014. He served as the President at ...
CEO Compensation Analysis
Compensation vs Market: Tim's total compensation ($USD242.26K) is about average for companies of similar size in the Swedish market ($USD231.20K).
Compensation vs Earnings: Tim's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & President | 7.25yrs | kr2.12m | 0.84% SEK 10.4m | |
| Chief Financial Officer | 0.58yr | no data | no data | |
| Chief Operating Officer | 1.17yrs | no data | no data | |
| President of China | 2.75yrs | no data | 0.059% SEK 734.0k | |
| President of EIMEA | 1.17yrs | no data | 0.0059% SEK 73.4k |
1.2yrs
Average Tenure
46yo
Average Age
Experienced Management: CRAD B's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Director | 1.75yrs | no data | 0.86% SEK 10.6m | |
| Independent Chairman of the Board | 4.25yrs | kr400.00k | 7.47% SEK 92.2m | |
| Independent Director | 3.75yrs | kr200.00k | no data | |
| Independent Director | 5.75yrs | kr200.00k | 0.018% SEK 220.3k | |
| Independent Director | 7.42yrs | kr200.00k | 2.11% SEK 26.1m | |
| Independent Director | 3.42yrs | kr200.00k | no data |
4.0yrs
Average Tenure
58yo
Average Age
Experienced Board: CRAD B's board of directors are considered experienced (4 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: CRAD B insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8.5%.
Top Shareholders
Company Information
C-Rad AB (publ)'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: C-Rad AB (publ)
- Ticker: CRAD B
- Exchange: OM
- Founded: 2004
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: kr1.235b
- Shares outstanding: 33.66m
- Website: https://www.c-rad.se
Number of Employees
Location
- C-Rad AB (publ)
- BredgrAend 18
- Uppsala
- Uppsala County
- 753 20
- Sweden
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| CRAD B | OM (OMX Nordic Exchange Stockholm) | Yes | Class B Shares | SE | SEK | Jul 2007 |
| 0R44 | LSE (London Stock Exchange) | Yes | Class B Shares | GB | SEK | Jul 2007 |
| CRADBS | BATS-CHIXE (BATS 'Chi-X Europe') | Yes | Class B Shares | GB | SEK | Jul 2007 |
Biography
C-Rad AB (publ), together with its subsidiaries, develops, manufactures, and sells systems with applications in radiation therapy for the treatment of cancer worldwide. The company operates through two seg ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/10/26 22:20 |
| End of Day Share Price | 2020/10/26 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.